Veracyte (VCYT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
Annual Meeting scheduled for June 10, 2026, to be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials and vote by June 9, 2026.
Voting matters and shareholder proposals
Election of nine directors to serve until the 2027 Annual Meeting or until successors are elected.
Ratification of Ernst & Young LLP as independent registered public accounting firm for 2026.
Advisory approval of executive compensation (say-on-pay) for named executive officers.
Approval of an amendment to the 2023 Equity Incentive Plan.
Proxies may vote on other business arising at the meeting or any adjournment.
Board of directors and corporate governance
Nine nominees are recommended for election to the board, including Eliav Barr, Muna Bhanji, Karin Eastham, Robert S. Epstein, Jens Holstein, Evan Jones, Tom Miller, Brent Shafer, and Marc Stapley.
Latest events from Veracyte
- Proxy covers director elections, auditor ratification, compensation, and equity plan changes.VCYT
Proxy filing23 Apr 2026 - Double-digit revenue and profit growth in 2025, with strong 2026 outlook and new launches ahead.VCYT
Q4 202513 Apr 2026 - Decipher and Afirma drive growth as Prosigna and MRD launches set the stage for future expansion.VCYT
Leerink Global Healthcare Conference 20269 Mar 2026 - Strong 2025 growth, new launches, and global expansion drive double-digit gains in 2026.VCYT
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q2 revenue up 27–28% to $114.4M, net income $5.7M, and 2024 guidance raised.VCYT
Q2 20242 Feb 2026 - Strong Q1 growth and new product launches position the company for continued market leadership.VCYT
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Decipher and Afirma drive strong growth, with new markets and innovations boosting future prospects.VCYT
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 2024 revenue up 29% to $115.9M, net income $15.2M, strong cash, and raised guidance.VCYT
Q3 202416 Jan 2026 - Strong financials, innovation, and global expansion drive growth in cancer diagnostics.VCYT
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026